Hayward, CA – According to filings with the U.S. Securities and Exchange Commission, Spotlight Therapeutics is raising $64,999,973.00 in new funding. Sources indicate as part of senior management President, Mary Haak-Frendscho played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Spotlight Therapeutics
Spotlight Therapeutics is a venture funded early-stage biotechnology company with a mission to develop a new class of therapeutics by enabling direct in vivo gene editing. Founded by Alex Marson (UCSF), Jacob Corn (UC Berkeley), and Patrick Hsu (Salk Institute) in December of 2017, Spotlight is building its core technology platform to achieve precise in vivo gene editing in targeted cell populations. With a therapeutic focus centered on oncology, our engineered nucleases edit the genes in targeted disease organs thereby inactivating or altering the gene product. We are hiring rapidly to build out our cutting-edge research and development team. This team is responsible for preclinical development ranging from protein engineering, gene editing to immuno-oncology and in vivo safety studies. Join us and work on the next generation of gene editing therapeutics in a fast-paced and exciting environment.

To learn more about Spotlight Therapeutics, visit http://www.spotlighttx.com/

Contact:
Mary Haak-Frendscho, President
510-405-5209
https://www.linkedin.com/in/mary-haak-frendscho-87333b11/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved